<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712448247</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712448247</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serum Uric Acid Levels are Associated With Atrial Fibrillation in Patients With Ischemic Heart Failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tekin</surname>
<given-names>Gulacan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712448247">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712448247"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tekin</surname>
<given-names>Yusuf Kenan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712448247">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Erbay</surname>
<given-names>Ali Rıza</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712448247">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turhan</surname>
<given-names>Hasan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319712448247">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yetkin</surname>
<given-names>Ertan</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0003319712448247">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712448247">
<label>1</label>Faculty of Medicine, Department of Cardiology, Bozok University, Yozgat, Turkey</aff>
<aff id="aff2-0003319712448247">
<label>2</label>Emergency Department, Yozgat State Hospital, Yozgat, Turkey</aff>
<aff id="aff3-0003319712448247">
<label>3</label>Department of Cardiology, Gozde Hospital, Malatya, Turkey</aff>
<aff id="aff4-0003319712448247">
<label>4</label>Department of Cardiology, Ortadogu Hospital, Mersin, Turkey</aff>
<author-notes>
<corresp id="corresp1-0003319712448247">Gulacan Tekin, Bozok University, Faculty of Medicine, Department of Cardiology, Bozok University, Yozgat, Turkey. Email: <email>gulacantekin@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>4</issue>
<fpage>300</fpage>
<lpage>303</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We evaluated the association between serum uric acid (SUA) and atrial fibrillation (AF) in patients with chronic heart failure (HF). Totally, 363 patients with chronic HF were included in the study. Of all, 78 patients had AF and 285 patients were in normal sinus rhythm. Serum uric acid was significantly increased in patients with AF compared with patients in normal sinus rhythm (<italic>P</italic> &lt; .05). Comparing patients with AF and normal sinus rhythm, we found that age was significantly higher in patients group with AF. Echocardiographic parameters including ejection fraction, left atrial diameter, left ventricle end-diastolic diameter, and left ventricle end-diastolic volume were also significantly higher in patients with AF compared with patients in normal sinus rhythm. We have shown that patients with AF have significantly higher SUA and this was independently associated with AF in patients with ischemic HF.</p>
</abstract>
<kwd-group>
<kwd>heart failure</kwd>
<kwd>atrial fibrillation</kwd>
<kwd>uric acid</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319712448247">
<title>Introduction</title>
<p>Uric acid (UA) is the end product of purine metabolism in humans.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712448247">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319712448247">2</xref>
</sup> Serum UA (SUA) is an independent predictor of cardiovascular disease and mortality in some studies.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712448247">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319712448247">4</xref>
</sup> Increased SUA was associated with severity of disease and an independent marker of poor prognosis in patients with heart failure (HF).<sup>
<xref ref-type="bibr" rid="bibr5-0003319712448247">5</xref>
</sup> Treatment with allopurinol during coronary artery bypass surgery reduced cardiovascular complications<sup>
<xref ref-type="bibr" rid="bibr6-0003319712448247">6</xref>
</sup> and decreased mortality and hospitalizations in patients with chronic HF.<sup>
<xref ref-type="bibr" rid="bibr7-0003319712448247">7</xref>,<xref ref-type="bibr" rid="bibr8-0003319712448247">8</xref>
</sup>
</p>
<p>Atrial fibrillation (AF) is a common arrhythmia. Recent studies suggest that SUA could be a marker of oxidative stress and inflammation involved in the mechanisms of AF and HF.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712448247">9</xref>
<xref ref-type="bibr" rid="bibr10-0003319712448247"/>–<xref ref-type="bibr" rid="bibr11-0003319712448247">11</xref>
</sup> In the Atherosclerosis Risk in Communities (ARIC) study, a population-based prospective cohort, including 15 382 patients, elevated SUA was associated with increased risk of AF among blacks and women but not in white men.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712448247">2</xref>
</sup> Levels of SUA are elevated in both patients with AF<sup>
<xref ref-type="bibr" rid="bibr2-0003319712448247">2</xref>,<xref ref-type="bibr" rid="bibr12-0003319712448247">12</xref>
</sup> and HF.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712448247">5</xref>,<xref ref-type="bibr" rid="bibr11-0003319712448247">11</xref>
</sup> The SUA measurements are available at low cost and may help assess prognosis of HF and AF.</p>
<p>We aimed to assess the association between SUA and chronic AF and normal sinus rhythm in patients with chronic ischemic HF. We also evaluated AF risk factors in patients with HF.</p>
</sec>
<sec id="section2-0003319712448247" sec-type="methods">
<title>Patients and Methods</title>
<p>Consecutive patients with ischemic HF (n = 363) were retrospectively included in this study from the outpatient cardiology clinic between June 2009 and August 2011. Patients with an echocardiographically determined ejection fraction ≤ 40% were included in the study. All patients have been received standard medical treatment. Patients with HF were divided into 2 groups: patients with chronic AF (n = 78) and patients with normal sinus rhythm (n = 285). The following clinical and demographic parameters were recorded: age, sex, hypertension (known hypertension treated with antihypertensive drugs, 2 or more blood pressure recordings greater than 140/90 mm Hg), diabetes mellitus (known diabetes treated with diet or drugs or both; or either a fasting serum glucose of more than 126 mg/dL), hypercholesterolemia (known treated hypercholesterolemia, or fasting or nonfasting serum cholesterol concentrations higher than 200 mg/dL). Current cigarette smoking was defined as active smoking within the past 12 months. All patients had coronary artery disease in whom coronary angiography was performed previously.</p>
<p>Patients with acute coronary syndromes, recent myocardial infarction (&lt;4 weeks), acute or chronic renal failure, infections within past 4 weeks, hematological diseases, active malignancies, and ejection fraction &gt;40% in echocardiography were not included in the study.</p>
<p>Hematological markers, glucose, total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and SUA levels were measured using an Architect CI16200 (Abbott, Germany) in all patients.</p>
<sec id="section3-0003319712448247">
<title>Statistical Analysis</title>
<p>Results are expressed as the mean ± standard deviation and percentages. The differences between the 2 groups were tested for significance by independent samples <italic>t</italic> test. Differences were considered significant at <italic>P</italic> &lt; .05 (2-tailed). We investigated the association of different variables with AF using logistic regression analysis. Parameters namely, age, gender, presence of hypertension, hyperlipidemia, diabetes mellitus, smoking status, and biochemical parameters such as glucose, urea, creatinine, total cholesterol, triglycerides, SUA, and echocardiographic parameters including ejection fraction and left atrial diameter were evaluated in the regression analysis. Statistical analyses were performed using SPSS 15.0 Statistical Package Program for Windows (SPSS Inc, Chicago, Illinois).</p>
</sec>
</sec>
<sec id="section4-0003319712448247">
<title>Results</title>
<p>The mean age of patients with HF with and without chronic AF was 71 ± 8 years and 66 ± 11 years, respectively (<italic>P</italic> &lt; .001). Baseline characteristics of patients with AF and normal sinus rhythm are presented in <xref ref-type="table" rid="table1-0003319712448247">Table 1</xref>. Presence of hypertension, gender, hyperlipidemia, diabetes mellitus, and smoking status were comparable between the 2 groups (<italic>P</italic> &gt; .05 for all). However, age and SUA were significantly higher in patients with AF compared with the normal sinus rhythm group. Ejection fraction, left atrial diameter, left ventricular end-diastolic diameter, and left ventricular end-diastolic volume were significantly higher in patients with AF compared with the normal sinus rhythm group. However, logistic regression analysis revealed that age, SUA, left atrial diameter, and left ventricular end-diastolic volume were significantly and independently associated with AF in patients with ischemic HF. Hypertension, gender, hyperlipidemia, diabetes mellitus, smoking, ejection fraction, and other confounding factors did not differ between the patients with AF and normal sinus rhythm (<xref ref-type="table" rid="table2-0003319712448247">Table 2</xref>).</p>
<table-wrap id="table1-0003319712448247" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of Patients With Atrial Fibrillation and Normal Sinus Rhythm with Ischemic Heart Failure.</p>
</caption>
<graphic alternate-form-of="table1-0003319712448247" xlink:href="10.1177_0003319712448247-table1.tif"/>
<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients With Atrial Fibrillation (n = 78)</th>
<th>Patients With Normal Sinus Rhythm (n = 285)</th>
<th>
<italic>P </italic>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>71 ± 8</td>
<td>66 ± 11</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Gender (female), %</td>
<td>30 (38%)</td>
<td>137 (48%)</td>
<td>.80</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>55 (71%)</td>
<td>214 (75%)</td>
<td>.51</td>
</tr>
<tr>
<td>Diabetes mellitus, %</td>
<td>16 (20%)</td>
<td>80 (28%)</td>
<td>.13</td>
</tr>
<tr>
<td>Hyperlipidemia, %</td>
<td>47 (61%)</td>
<td>197 (69%)</td>
<td>.18</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>41 (53%)</td>
<td>137 (48%)</td>
<td>.36</td>
</tr>
<tr>
<td>White blood cell, ×10<sup>3</sup>/μL</td>
<td>7.7 ± 1.9</td>
<td>7.6 ± 2.5</td>
<td>.67</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>112 ± 37</td>
<td>119 ± 55</td>
<td>.31</td>
</tr>
<tr>
<td>Urea, mg/dL</td>
<td>19.5 ± 6.9</td>
<td>18.09 ± 7.6</td>
<td>.15</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>1.06 ± 0.24</td>
<td>1.00 ± 0.26</td>
<td>.10</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>167 ± 49</td>
<td>178 ± 44</td>
<td>.06</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>119 ± 74</td>
<td>129 ± 62</td>
<td>.21</td>
</tr>
<tr>
<td>LDL-cholesterol, mg/dL</td>
<td>108 ± 33</td>
<td>115 ± 36</td>
<td>.12</td>
</tr>
<tr>
<td>Uric acid, mg/dL</td>
<td>6.4 ± 2.09</td>
<td>5.7 ± 1.9</td>
<td>.002</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>33.3 ± 6.6</td>
<td>35.6 ± 5.4</td>
<td>.006</td>
</tr>
<tr>
<td>Left atrial diameter, mm</td>
<td>44 ± 6</td>
<td>38 ± 5</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LVEDD, mm</td>
<td>47 ± 7</td>
<td>42 ± 7</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LVEDV, mL</td>
<td>151 ± 48</td>
<td>131 ± 46</td>
<td>.003</td>
</tr>
<tr>
<td>Diuretic use, %</td>
<td>42 (56%)</td>
<td>136 (48%)</td>
<td>.23</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712448247">
<p>Abbreviations: LDL, low-density lipoprotein; LVEDD, left ventricular end diastolic diameter; LVEDV, left ventricular end diastolic volume.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0003319712448247" position="float">
<label>Table 2.</label>
<caption>
<p>Logistic Regression Analysis.</p>
</caption>
<graphic alternate-form-of="table2-0003319712448247" xlink:href="10.1177_0003319712448247-table2.tif"/>
<table>
<thead>
<tr>
<th>Variables</th>
<th>Odds Ratio</th>
<th>Confidence Interval</th>
<th>
<italic>P </italic>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>1.05</td>
<td>1.01 ± 1.09</td>
<td>.007</td>
</tr>
<tr>
<td>Hypertension</td>
<td>0.73</td>
<td>0.32 ± 1.66</td>
<td>.46</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0.64</td>
<td>0.23 ± 1.73</td>
<td>.38</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>1.19</td>
<td>0.50 ± 2.83</td>
<td>.68</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.22</td>
<td>0.60 ± 2.47</td>
<td>.56</td>
</tr>
<tr>
<td>Glucose, mg/dL</td>
<td>1.00</td>
<td>0.99 ± 1.00</td>
<td>.68</td>
</tr>
<tr>
<td>Urea, mg/dL</td>
<td>0.95</td>
<td>0.90 ± 1.00</td>
<td>.09</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>0.99</td>
<td>0.99 ± 1.00</td>
<td>.80</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>1.00</td>
<td>0.99 ± 1.00</td>
<td>.97</td>
</tr>
<tr>
<td>Uric acid, mg/dL</td>
<td>1.27</td>
<td>1.06 ± 1.52</td>
<td>.01</td>
</tr>
<tr>
<td>Ejection fraction</td>
<td>0.99</td>
<td>0.93 ± 1.06</td>
<td>.95</td>
</tr>
<tr>
<td>Left atrial diameter</td>
<td>6.00</td>
<td>3.06 ± 11.76</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LVEDV</td>
<td>0.99</td>
<td>0.99 ± 1.00</td>
<td>.83</td>
</tr>
<tr>
<td>Diuretic use, %</td>
<td>0.70</td>
<td>0.32 ± 1.54</td>
<td>.38</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319712448247">
<p>Abbreviation: LVEDV, left ventricular end diastolic volume.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-0003319712448247">
<title>Discussion</title>
<p>We assessed the association between SUA and AF in patients with HF. Risk factors for AF were also evaluated. It is thought that SUA was as an independent risk factor for cardiovascular morbidity and mortality.<sup>
<xref ref-type="bibr" rid="bibr4-0003319712448247">4</xref>
</sup> Hyperuricemia is often found in patients with chronic HF and it is associated with the severity and prognosis of disease. Elevated SUA levels were also found in coronary artery disease, hypertension, stroke, metabolic syndrome, insulin resistance, obesity, diuretic treatment, and reduced renal excretion.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712448247">5</xref>,<xref ref-type="bibr" rid="bibr13-0003319712448247">13</xref>
</sup>
</p>
<p>Atrial fibrillation is associated with an increased left atrial size and elevated SUA levels. Increased left atrial size is a significant factor that facilitates the initiation and perpetuation of AF and associated prothrombotic state.<sup>
<xref ref-type="bibr" rid="bibr14-0003319712448247">14</xref>
</sup> Serum UA is produced by purine catabolism. End terminal steps of this catabolism are catalyzed by xanthine oxidoreductase. Xanthine oxidoreductase is found in the left atrium in patients with AF.<sup>
<xref ref-type="bibr" rid="bibr10-0003319712448247">10</xref>
</sup> A cross-sectional study reported an independent association between SUA levels and AF in hypertensive patients.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712448247">9</xref>
</sup>
</p>
<p>It was hypothesized that increased SUA was a marker of oxidative damage and inflammation which are involved in the pathogenesis of AF and HF.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712448247">2</xref>,<xref ref-type="bibr" rid="bibr11-0003319712448247">11</xref>
</sup> Recently, another case–control study observed an association between permanent AF and SUA.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712448247">12</xref>
</sup>
</p>
<p>The association between SUA and AF may be explained by oxidative stress<sup>
<xref ref-type="bibr" rid="bibr2-0003319712448247">2</xref>,<xref ref-type="bibr" rid="bibr10-0003319712448247">10</xref>,<xref ref-type="bibr" rid="bibr13-0003319712448247">13</xref>
</sup> which play a role in the pathogenesis of AF and HF. Valvular and postcoronary arterial bypass grafting was related to AF that was associated with oxidative stress.<sup>
<xref ref-type="bibr" rid="bibr15-0003319712448247">15</xref>
</sup> Serum UA is a marker of endothelial dysfunction in the metabolic syndrome and diabetes, all of which are important predictors of AF.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712448247">2</xref>
</sup> Dyslipidemia which is a component of metabolic syndrome was associated with SUA level and treatment with atorvastatin reduced SUA levels in patients with coronary heart disease.<sup>
<xref ref-type="bibr" rid="bibr16-0003319712448247">16</xref>
</sup>
</p>
<p>The variability in SUA levels is multifactorial and influenced by disease, environmental, and genetic factors.<sup>
<xref ref-type="bibr" rid="bibr17-0003319712448247">17</xref>
</sup> The risk is with SUA levels in the high normal range as well.<sup>
<xref ref-type="bibr" rid="bibr18-0003319712448247">18</xref>
</sup> Deficient excretion of UA may have contributed to increased SUA levels.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712448247">9</xref>
</sup> Oxidative damage may contribute to atrial remodeling during AF. Several pathophysiological changes that are possibly responsible for increased oxidative stress in AF gene transcriptional profiles and mitochondrial DNA, increased activity of enzymes such as NAD(P)H oxidase and xanthine oxidase, inflammatory processes, activation of the renin–angiotensin system and others.<sup>
<xref ref-type="bibr" rid="bibr10-0003319712448247">10</xref>
</sup>
</p>
<p>Diagnosis and treatment of AF are important because it is independently associated with increased cardiovascular morbidity and mortality.<sup>
<xref ref-type="bibr" rid="bibr19-0003319712448247">19</xref>
</sup>
<sup>,</sup>
<sup>
<xref ref-type="bibr" rid="bibr20-0003319712448247">20</xref>
</sup> Chronic HF is associated with hyperuricemia, increased circulating markers of inflammation, and oxidative stress.<sup>
<xref ref-type="bibr" rid="bibr5-0003319712448247">5</xref>,<xref ref-type="bibr" rid="bibr13-0003319712448247">13</xref>
</sup> Activation of xanthine oxidase provides free radical release, causes leukocyte and endothelial cell activation.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712448247">11</xref>,<xref ref-type="bibr" rid="bibr13-0003319712448247">13</xref>
</sup> This mechanism is also present in pathogenesis of AF. So it is expected that there is an association between SUA level and markers of inflammation. Atrial fibrillation with HF may result in additional cardiovascular risk. Leyva et al reported that SUA was related to circulating markers of inflammation in patients with chronic HF compared with normal healthy controls. Hyperuricemia was also evaluated as a marker of impaired oxidative metabolism, insulin resistance.<sup>
<xref ref-type="bibr" rid="bibr11-0003319712448247">11</xref>
</sup>
</p>
<sec id="section6-0003319712448247">
<title>Study Limitations</title>
<p>The number of participants was relatively small and our study was retrospective. Future studies should also assess HF-related markers such as brain natriuretic peptide, C-reactive protein, tumor necrosis factor α, and interleukin 1.</p>
<p>In conclusion, we found an association between SUA and AF in patients with ischemic HF. Further randomized, prospective studies are needed to confirm this association and assess its potential clinical relevance.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712448247">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712448247">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712448247">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?</article-title> <source>Med Hypotheses</source>. <year>2008</year>;<volume>70</volume>(<issue>3</issue>):<fpage>578</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712448247">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamariz</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Soliman</surname>
<given-names>EZ</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] Study)</article-title>. <source>Am J Cardiol</source>. <year>2011</year>;<volume>108</volume>(<issue>9</issue>):<fpage>1272</fpage>–<lpage>1276</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712448247">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liese</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Hense</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Löwel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Döring</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tietze</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Keil</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases</article-title>. <source>Epidemiology</source>. <year>1999</year>;<volume>10</volume>(<issue>4</issue>):<fpage>391</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712448247">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoieggen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alderman</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kjeldsen</surname>
<given-names>SE</given-names>
</name>
<etal/>
</person-group>. <article-title>The impact of serum uric acid on cardiovascular outcomes in the LIFE study</article-title>. <source>Kidney Int</source>. <year>2004</year>;<volume>65</volume>(<issue>3</issue>):<fpage>1041</fpage>–<lpage>1049</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712448247">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anker</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Doehner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Rauchhaus</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>(<issue>15</issue>):<fpage>1991</fpage>–<lpage>1997</lpage>.</citation>
</ref>
<ref id="bibr6-0003319712448247">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weimert</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Tanke</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Sims</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Allopurinol as a cardioprotectant during coronary artery bypass graft surgery</article-title>. <source>AnnPharmacother</source>. <year>2003</year>;<volume>37</volume>(<issue>11</issue>):<fpage>1708</fpage>–<lpage>1711</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712448247">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cappola</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Kass</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>GS</given-names>
</name>
<etal/>
</person-group>. <article-title>Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>20</issue>):<fpage>2407</fpage>–<lpage>2411</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712448247">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Struthers</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Donnan</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Lindsay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>McNaughton</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Broomhall</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Macdonald</surname>
<given-names>TM</given-names>
</name>
</person-group>. <article-title>Effect of allopurinol on mortality and hospitalizations in congestive heart failure: a retrospective cohort study</article-title>. <source>Heart</source>. <year>2002</year>;<volume>87</volume>(<issue>3</issue>):<fpage>229</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712448247">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Korantzopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Uric acid levels and atrial fibrillation in hypertensive patients</article-title>. <source>Intern Med</source>. <year>2011</year>;<volume>50</volume>(<issue>8</issue>):<fpage>799</fpage>–<lpage>803</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712448247">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korantzopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kolettis</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Galaris</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Goudevenos</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation</article-title>. <source>Int J Cardiol</source>. <year>2007</year>;<volume>115</volume>(<issue>2</issue>):<fpage>135</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712448247">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leyva</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Anker</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Godsland</surname>
<given-names>IF</given-names>
</name>
<etal/>
</person-group>. <article-title>Uric acid in chronic heart failure: a marker of chronic inflammation</article-title>. <source>Eur Heart J</source>. <year>1998</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1814</fpage>–<lpage>1822</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712448247">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letsas</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Korantzopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Filippatos</surname>
<given-names>GS</given-names>
</name>
<etal/>
</person-group>. <article-title>Uric acid elevation in atrial fibrillation</article-title>. <source>Hellenic J Cardiol</source>. <year>2010</year>;<volume>51</volume>(<issue>3</issue>):<fpage>209</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712448247">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lippi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Montagnana</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Franchini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Favaloro</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Targher</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>The paradoxical relationship between serum uric acid and cardiovascular disease</article-title>. <source>Clin Chim Acta</source>. <year>2008</year>;<volume>392</volume>(<issue>1-2</issue>):<fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712448247">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagliardi</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Miname</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Uric acid: a marker of increased cardiovascular risk</article-title>. <source>Atherosclerosis</source>. <year>2009</year>;<volume>202</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712448247">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casaclang-Verzosa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gersh</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>TS</given-names>
</name>
</person-group>. <article-title>Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712448247">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Inden</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation</article-title>. <source>Heart Rhythm</source>. <year>2009</year>;<volume>6</volume>(<issue>7</issue>):<fpage>935</fpage>–<lpage>940</lpage>.</citation>
</ref>
<ref id="bibr17-0003319712448247">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Papageorgiou</surname>
<given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study</article-title>. <source>Am J Kidney Dis</source>. <year>2004</year>;<volume>43</volume>(<issue>4</issue>):<fpage>589</fpage>–<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr18-0003319712448247">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nath</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Voruganti</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Arar</surname>
<given-names>NH</given-names>
</name>
<etal/>
</person-group>. <article-title>Genome scan for determinants of serum uric acid variability</article-title>. <source>J Am Soc Nephrol</source>. <year>2007</year>;<volume>18</volume>(<issue>12</issue>):<fpage>3156</fpage>–<lpage>3163</lpage>.</citation>
</ref>
<ref id="bibr19-0003319712448247">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feig</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Uric acid and cardiovascular risk</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>359</volume>:<fpage>1811</fpage>–<lpage>1821</lpage>.</citation>
</ref>
<ref id="bibr20-0003319712448247">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chugh</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Blackshear</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Hammill</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Gersh</surname>
<given-names>BJ</given-names>
</name>
</person-group>. <article-title>Epidemiology and natural history of atrial fibrillation: clinical implications</article-title>. <source>J Am Coll Cardiol</source>. <year>2001</year>;<volume>37</volume>(<issue>2</issue>):<fpage>371</fpage>–<lpage>378</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>